Intra-cellular therapies, inc. (ITCI)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Sep'12
Revenue

1,083

-

-

-

-

-

-

-

-

5

30

114

95

-

4

228

-

30

0

57

3

65

124

219

167

827

667

643

598

377

Operating expenses:
Cost of product sales

69

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development

16,003

19,065

21,339

23,728

24,990

33,605

35,419

32,439

30,702

26,929

18,472

12,478

21,538

21,179

23,918

25,300

23,433

22,865

28,457

17,762

18,632

11,641

4,046

2,709

2,829

6,129

4,157

7,787

4,952

1,797

Selling, general and administrative

34,096

-

-

-

11,704

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

General and administrative

-

-

15,036

15,442

-

9,017

7,972

6,728

6,381

5,784

5,317

6,254

6,310

6,951

6,270

6,471

5,064

6,538

3,891

3,985

3,771

3,721

2,581

2,121

1,912

2,730

1,295

903

1,046

802

Total operating expenses

50,169

41,829

36,376

39,171

36,695

42,622

43,391

39,168

37,084

32,713

23,789

18,733

27,849

28,130

30,188

31,772

28,497

29,403

32,349

21,748

22,404

15,362

6,628

4,830

4,742

8,860

5,453

8,691

5,998

2,599

Loss from operations

-49,085

-41,768

-36,376

-39,171

-36,695

-42,622

-43,391

-39,168

-37,084

-32,708

-23,759

-18,618

-27,754

-28,032

-30,184

-31,544

-28,497

-29,372

-32,349

-21,690

-22,400

-15,297

-6,503

-4,611

-4,574

-8,032

-4,785

-8,048

-5,400

-2,221

Interest income

1,678

1,185

1,513

1,731

1,860

1,874

1,868

1,793

1,604

1,441

884

857

822

805

763

709

656

540

188

179

113

99

88

80

36

18

5

2

3

6

Interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

12

-

-

-

-

-

-

0

0

2

5

8

131

231

241

-

Loss before provision for income taxes

-47,407

-40,582

-34,862

-37,439

-34,835

-40,748

-41,522

-37,374

-35,480

-31,267

-22,874

-17,760

-26,931

-27,251

-29,432

-30,834

-27,841

-

-32,160

-

-

-

-

-

-

-

-

-

-

-

Income tax expense

3

-

-

1

-

-

-

1

-

-1,058

-4

0

1

-

832

-

-

-

-

-

-

-

-

-

-

-

-

0

-8

8

Net loss

-47,410

-40,582

-34,862

-37,441

-34,835

-40,748

-41,522

-37,376

-35,480

-30,208

-22,870

-17,760

-26,933

-27,485

-30,265

-30,834

-27,841

-28,834

-32,160

-21,511

-22,286

-15,199

-6,415

-4,533

-4,543

-8,040

-4,911

-8,277

-5,638

-2,223

Net loss per common share:
Basic & Diluted

-0.73

-0.74

-0.63

-0.68

-0.63

-0.75

-0.76

-0.68

-0.65

-0.56

-0.53

-0.41

-0.62

-0.64

-0.70

-0.71

-0.64

-0.67

-0.91

-0.61

-0.72

-0.53

-0.22

-0.15

-0.17

-0.33

-0.28

-0.56

-0.39

-

Basic

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.40

Dilutive

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.40

Weighted average number of common shares:
Basic & Diluted

65,106

55,278

55,207

55,145

55,113

54,750

54,708

54,696

54,676

54,497

43,424

43,419

43,385

43,273

43,253

43,239

43,193

43,178

35,320

35,002

30,775

29,471

29,379

29,273

26,475

22,224

17,527

14,690

14,599

5,607

Product sales, net [Member]
Revenue

882

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Grant revenue [Member]
Revenue

200

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-